Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Abstract

Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.

What is claimed is: 
     
         1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . A method of treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels comprising administering to an adult human in need thereof a peptide comprising the amino acid sequence of SEQ ID NO: 193 at a weekly dosage of about 1 mg to about 40 mg per week. 
     
     
         5 . The method of  claim 4 , wherein the weekly dosage is about 2 mg to about 10 mg 
     
     
         6 . The method of  claim 4 , wherein the adult human has diabetes mellitus type I, diabetes mellitus type II, or gestational diabetes. 
     
     
         7 . The method of  claim 4 , wherein the peptide is administered once per week. 
     
     
         8 . The method of  claim 4 , wherein the peptide is administered twice per week. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 4 , further comprising administering a second therapeutic agent. 
     
     
         18 . The method of  claim 17 , wherein the second therapeutic agent is an anti-diabetic agent. 
     
     
         19 . The method of  claim 17 , wherein the second therapeutic agent is an anti-obesity agent. 
     
     
         20 . The method of  claim 4 , wherein the peptide is administered in a pharmaceutical composition. 
     
     
         21 . The method of  claim 20 , wherein the pharmaceutical composition is administered via subcutaneous, intravenous, or intramuscular injection. 
     
     
         22 . The method of  claim 21 , wherein the pharmaceutical composition is administered by subcutaneous injection. 
     
     
         23 . The method of  claim 4 , wherein administration of the peptide results in an increase in insulin level, a decrease in glucose level, an increase in C-peptide level, a decrease in HbA 1c  level, or a decrease in fructosamine level, or any combination thereof. 
     
     
         24 . The method of  claim 20 , wherein the peptide is administered from a pre-filled syringe. 
     
     
         25 . The method of  claim 4 , wherein the amino acid at position 24 is a Cys, Lys, Orn, homocysteine, or acetyl-phenylalanine covalently linked to a hydrophilic group. 
     
     
         26 . The method of  claim 25 , wherein the amino acid at position 24 is a Cys covalently linked to a hydrophilic group. 
     
     
         27 . The method of  claim 4 , wherein the amino acid at position 24 of the peptide is covalently linked to a hydrophilic polymer. 
     
     
         28 . The method of  claim 27 , wherein the hydrophilic polymer is a polyethylene glycol (PEG) moiety. 
     
     
         29 . The method of  claim 28 , wherein the PEG moiety has a molecular weight of about 30,000 Daltons to about 60,000 Daltons. 
     
     
         30 . The method of  claim 29 , wherein the PEG moiety has a molecular weight of about 40,000 Daltons.